Skip to main content

NeoGenomics, Inc.

corporate_fare Company Profile

NeoGenomics, Inc.

NEO·NASDAQ·Industrial Applications And Services·CIK 0001077183

NeoGenomics, Inc. provides oncology diagnostic testing and consultative services. These services include technical laboratory services and professional interpretation of test results by licensed physicians or molecular experts specializing in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. As of December 31, 2025, NeoGenomics operated College of American Pathologists (CAP) accredited and Clinical Laboratory Improvement Amendments of 1988 (CLIA) certified laboratories in Fort Myers, Florida; Aliso Viejo and Carlsbad, California; Durham, North Carolina; Ramsey, New Jersey; and Houston, Texas. It also operated an International Organization for Standardization (ISO) certified, CAP accredited full-service, sample-processing laboratory in Cambridge, United Kingdom. Additionally, the company has several small, non-processing laboratory locations across the United States for analysis services. NeoGenomics offers Cytogenetics (karyotype analysis), which is the study of normal and abnormal chromosomes and their relationship to disease, involving the analysis of chromosome structure to identify changes from normal patterns. These studies provide diagnostic, prognostic, and occasionally predictive information for patients with hematological malignancies. The company also offers Fluorescence In-Situ Hybridization (FISH), a molecular cytogenetic technique that detects and localizes specific DNA sequences and genes on chromosomes using fluorescent probes visualized by fluorescence microscopy.

NeoGenomics, Inc. (NASDAQ:NEO) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 23 items for NEO at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-28, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 8 rated 8 or above. Recent SEC coverage for NEO spans 8-K, 10-Q, DEF 14A.

Recent high-impact activity:

  • NeoGenomics Q3 Revenue Up 11% to $209M, Raises Full-Year 2026 Guidance
  • NeoGenomics Posts 6-Cent Q3 Loss Per Share
  • NeoGenomics Plunges 12% as Leadership Shakeup and Q3 Beat Fail to Impress
  • NeoGenomics Names Warren Stone CEO, Posts Preliminary Q3 Revenue of $209M
  • NeoGenomics Names Warren Stone CEO, Prelim Q3 Revenue Tops $209M

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$727.33M
Net Income
-$108.03M
Op. Cash Flow
$5.23M
Free Cash Flow
-$21.78M
Gross Profit
$314.29M
Operating Income
-$115.88M
Cash & Equivalents
$159.62M
Total Debt
$341.86M
Debt / Equity
0.41×
Net Margin
-14.9%
Shares Outstanding
128.15M sh
Source: 10-K · filed 2026-02-17 · accession 0001077183-26-000010

Short Interest & Short Volume

6.67 days to cover

FINRA reported short interest of 13,134,507 shares in NEO as of the October 30, 2026 settlement, a 7.6% decrease from the prior period — about 6.7 days to cover at its recent average daily volume. On November 19, 2026, 87.6% of NEO volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)13,134,507 shares as of October 30, 2026
Change vs prior period▼ 7.6%
Days to cover6.67 at avg daily volume of 1,969,147
Daily short volume (FINRA facilities)87.6% of 1,104,656 shares on November 19, 2026
5-day average short volume71.6%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Low risk

Filing-implied dilution signals for NEO, detected from its recent SEC filings · based on capital-structure filings through 2026-06-22.

Finalized Convertible Senior Notes Offering · Premium Conversion Price

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with N →
$14.65 -2.92% today
52-week range · as of 2026-10-28 $7.07 – $20.15
Market cap
$1.9B
Volume
651.4K (0.4× avg)
3-mo avg 1.7M
Live data · 2026-11-20 20:39 UTC · Market open

show_chartPrice Chart

Loading chart...

feed NEO - Latest Insights

NEO
Oct 28, 2026, 4:06 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $18.45
Real-time Price: $14.65 info
Change: -$3.80 (-21%) info
Market Cap: $1.897B info
NEO
Oct 28, 2026, 4:05 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $18.00
Real-time Price: $14.65 info
Change: -$3.35 (-19%) info
Market Cap: $1.897B info
NEO
Oct 06, 2026, 1:37 PM EDT
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $16.70
Real-time Price: $14.65 info
Change: -$2.05 (-12%) info
Market Cap: $1.897B info
NEO
Oct 05, 2026, 4:08 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $18.93
Real-time Price: $14.65 info
Change: -$4.28 (-23%) info
Market Cap: $1.897B info
NEO
Oct 05, 2026, 4:05 PM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $19.10
Real-time Price: $14.65 info
Change: -$4.45 (-23%) info
Market Cap: $1.897B info
NEO
Aug 26, 2026, 4:17 PM EDT
Source: BusinessWire
Importance Score:
8
Price at Filing: $16.45
Real-time Price: $14.65 info
Change: -$1.80 (-11%) info
Market Cap: $1.897B info
NEO
Jul 28, 2026, 4:09 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $14.18
Real-time Price: $14.65 info
Change: +$0.4679 (+3%) info
Market Cap: $1.897B info
NEO
Jul 28, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $14.25
Real-time Price: $14.65 info
Change: +$0.400 (+3%) info
Market Cap: $1.897B info
NEO
Jul 20, 2026, 5:27 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $14.24
Real-time Price: $14.65 info
Change: +$0.410 (+3%) info
Market Cap: $1.897B info
NEO
Jul 20, 2026, 5:23 PM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $14.24
Real-time Price: $14.65 info
Change: +$0.410 (+3%) info
Market Cap: $1.897B info
NEO
Jun 25, 2026, 7:10 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $12.92
Real-time Price: $14.65 info
Change: +$1.73 (+13%) info
Market Cap: $1.897B info
NEO
Jun 22, 2026, 5:17 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $11.20
Real-time Price: $14.65 info
Change: +$3.45 (+31%) info
Market Cap: $1.897B info
NEO
Jun 17, 2026, 6:05 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $10.40
Real-time Price: $14.65 info
Change: +$4.25 (+41%) info
Market Cap: $1.897B info
NEO
Jun 15, 2026, 5:33 PM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $10.72
Real-time Price: $14.65 info
Change: +$3.93 (+37%) info
Market Cap: $1.897B info
NEO
Jun 15, 2026, 5:24 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $11.09
Real-time Price: $14.65 info
Change: +$3.56 (+32%) info
Market Cap: $1.897B info
NEO
May 22, 2026, 4:19 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $9.23
Real-time Price: $14.65 info
Change: +$5.42 (+59%) info
Market Cap: $1.897B info
NEO
Apr 28, 2026, 5:01 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $9.04
Real-time Price: $14.65 info
Change: +$5.61 (+62%) info
Market Cap: $1.897B info
NEO
Apr 28, 2026, 4:59 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $9.04
Real-time Price: $14.65 info
Change: +$5.61 (+62%) info
Market Cap: $1.897B info
NEO
Apr 28, 2026, 4:05 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $9.02
Real-time Price: $14.65 info
Change: +$5.63 (+62%) info
Market Cap: $1.897B info
NEO
Apr 06, 2026, 4:22 PM EDT
Filing Type: DEF 14A
Importance Score:
9
Price at Filing: $8.02
Real-time Price: $14.65 info
Change: +$6.63 (+83%) info
Market Cap: $1.897B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets